Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00949975 · ClinicalTrials.gov registry record · Phase 2
A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 838
- Enrollment target
NCT00949975 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 838 participants.
The verdict
NCT00949975, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 838 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the dose-response relationship and efficacy of AZD9668 at 3 dose levels compared with placebo in symptomatic COPD patients by assessing effects on lung function and symptoms of COPD.
Interventions
- DRUG AZD9668
- DRUG AZD9668 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 838 participants |
| Start Date | 2009-07 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00949975
The ClinicalTrials.gov registry entry for NCT00949975 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 838 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AZD9668 is the first listed.
NCT00949975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00949975 about?
NCT00949975 is a clinical study titled "A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium". The primary objective is to evaluate the dose-response relationship and efficacy of AZD9668 at 3 dose levels compared with placebo in symptomatic COPD patients by assessing effects on lung function and symptoms of COPD.
What is the current status of trial NCT00949975?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 838 participants. The study started on 2009-07. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00949975?
The interventions under investigation include: AZD9668 (DRUG), AZD9668 Placebo (DRUG).
Who is sponsoring clinical trial NCT00949975?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.